Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
C3S2 GmbH has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active prosecution involves 1 distinct examiner and 1 distinct art unit, indicating a consolidated interaction with the patent office. In the complex field of biotechnology, this concentration suggests that the company is currently prioritizing a specific therapeutic or diagnostic innovation. For the practitioner, this means that the immediate success of the company's patent strategy depends on the resolution of this single pending matter, with no other active applications to diversify the prosecution risk across different art units.
BURKHART, MICHAEL D is the busiest examiner, overseeing 1 busiest examiner pending action. This single action accounts for the total 1 pending office action for the portfolio, placing the current prosecution outcome under the review of this specific examiner. Because the busiest examiner handles the only active action, their feedback and requirements are the sole focus for the company's legal efforts. A successful outcome will require a response strategy that is specifically tailored to this examiner's concerns, as there are no other pending actions to provide alternative opportunities for securing patent protection.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411732 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | BURKHART, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411732 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | BURKHART, MICHAEL D | 1638 | §103Other | Final Rejection | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialC3S2 GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Burkhart has the most, with 1 of C3S2 GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
